Canada markets closed

Khiron Life Sciences Corp. (KHRNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2268-0.0044 (-1.90%)
At close: 3:59PM EDT
Sign in to post a message.
  • A
    Adrian
    Can someone explain these numbers for me . Annual revenue went from 9.5m(2019) to 8 m(2020). Annual salaries went from 6.7(2019m to 11.8m (2020). Why on earth are they raising salaries while business was slowing down? I can only imagine salaries to keep going up for 2021. Rev will likely go up this year but i doubt it would even cover the salaries .
  • W
    Weed Warrior
  • L
    Leonardo
    this is a long term stock, either because of the dividends or the valuation of the company, I am sure that we are sitting on a gold mine and that we will soon see the precious metal shining.

    The key word is: PATIENCE
  • J
    Jason
    When is the bleed going to stop? You gotta think it’s going to pop back up soon right?
  • j
    james
    not sure approved the stock would go down due to mexico legalization. they already have approved medical which is what khiron does anyways!
  • R
    Roland
    I am in at .40 when will I see green ? Are we thinking months or years ?
  • A
    Adrian
    I have been following this company pretty loose, but what is the reason after the massive sell off? last quarter didn't seem too terrible and sp didn't react to that, but only reacted after the dilution has occurred. Is it merely a negative reaction towards the dilution and/or a lack of execution on management? Market cap is 58m with 19 m cash , far exceeding the liabilities we hold, yet it's trading near ATL. Seems like great value based on the stage it is at. Are there political concerns getting in the way of their expansion in south america + mexico?
  • B
    Bernard
    I don't really know what people here would prefer, Khiron to not raise money and expand more quickly in mexico and Brazil or Khiron to not expand in these market and wait until the competition has already saturated these markets? judging by people's complaints here I'm unsure. Q2 Renevu will most likely be around 1 million from medical cannabis Q2, an increase from the 500k in Q1. They need around 6-7 million in cannabis revenue to break even around Q1 2022, how are they supposed to do that without quick expansion? 🤔
  • A
    Adrian
    why is the insider ownership so low and why are they not picking up shares at these levels?
  • j
    james
    volume has been high all week. over 1 million shares most days. problem is it keeps going down in price and I KEEP BUYING. HOPE IT TURNS AROUND SOON!! TED OBASHI SAYS IT IS A SCREAMING BUY EVEN WITH THE MONEY THEY JUST RAISED TO OPEN UP MEXICO! HOW CAN THIS LOSE 12 CTS IN A COUPLE WEEKS. SOMEONE IS PLAYING GAMES WITH THIS STOCK.
  • M
    Mike
    Management gets paid huge while the company tanks. Only way is to go long on short position to make money
  • P
    Philip
    Dilution smulution, every lp/MSO has diluted a million times , please make me aware of any LP/MSO that has carved their own path with minimal competition in their area ? Or any lp / MSO with a former president of a country or president of one of the biggest companies on this earth ? This is the first inning. Khiron is setting the framework for others to follow. If they need to raise capital to expand into Mexico and Brazil go right ahead. .47 cents is a joke this should be at 2+
  • S
    Sachin
    Khiron Life Sciences Comprehensive ESG Strategy Will Pay Dividends Going Into The Future..
  • j
    jon
    Khiron successfully completes first medical cannabis sale in Brazil
    Download as PDFJULY 02, 2021 8:30AM EDT
    With over 200 million people, Brazil is Latin America´s largest addressable medical cannabis market, with the potential to reach USD$1.4 billion in annual revenue (Source: New Frontier Data)
    In partnership with leading medical cannabis patient association in Brazil, a child with epilepsy becomes first Brazilian patient to receive Khiron medical cannabis product
    Khiron plans to expand Zerenia™ vertically integrated clinic model into Brazil, increasing patient access to affordable, high-quality medical cannabis products
    TORONTO, July 2, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce it has successfully completed its first sale of medical cannabis product in Brazil. Leveraging production, distribution, and clinical assets in Latin America, along with marketing agreements with leading pharmaceutical distributors, Khiron plans to expand its presence in Brazil, a market of over 200 million people.

    Khiron Life Sciences Corp Brazil Logo (CNW Group/Khiron Life Sciences Corp.)

    "Our initial export to the Brazilian market represents an important first step toward opening a large, underserved market where patients face high barriers to access. By providing patients with affordable high-quality products, and an unparalleled patient experience, we see an opportunity to disrupt the Brazilian market and deliver on our mission of improving patients lives. Khiron is already treating thousands of patients in Colombia, Peru, UK and Germany, with positive outcomes. In due course, we plan to bring our successful Zerenia clinic model to Brazil, as we have done in Peru and Colombia," comments Alvaro Torres, CEO and Director.

    Through the Company´s strategic alliance with CANNAB, a patient association that connects physicians, patients, academic institutions, and suppliers, a three-year old child from Salvador de Bahia suffering from epilepsy has received six units of Khiron high-CBD 100mg/50ml extract. The importation of Khiron's medical cannabis on behalf of the patient was authorized by ANVISA (the Brazilian National Health Surveillance Agency). The Company plans to collaborate with CANNAB to continue offering its medical products to many more patients. CANNAB expects to help over 1,200 new patients gain access to medical cannabis products during 2021. According to Prohibition Partners, the Brazilian medical cannabis user base could reach close to 3 million people in the next few years.

    The Company has also established two partnerships in Brazil to increase product awareness and medical cannabis education for health care providers across the country. As previously announced, Khiron has an exclusive agreement with Medlive, a pharmaceutical and health products distributor with a network of over 3,000 clinics and hospitals in southern Brazil. In addition, the Company has signed a marketing contract with TAIMIN, a leading medical distributor focused on Rio de Janeiro, Sao Paulo and northern Brazil. Together, the two agreements provide broad regional coverage across Brazil and are intended to drive sales by expanding Khiron's network of prescribing physicians. The Company is also in discussion with several medical clinics as it seeks to expand its clinic model into Brazil.

    About Khiron Life Sciences Corp.
    Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Brazil, Germany and the UK, and is positioned to commence sales in Mexico in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
  • j
    james
    now is the time it goes up. volume reduced and more people buying, the train is leaving.
  • j
    jon
    Khiron Cannabis Co To Debut South Of The Border, Obtains High-THC Extract Export Quotas For Mexico
    by
    Jelena Martinovic
    June 28, 2021 2:54 pm
    Share to Linkedin
    Share to Twitter
    Share to Facebook
    Share to Print
    License
    More
    Thousands of traders just like you are using Benzinga Options to learn the formula that Nic Chahine uses to earn a full-time living. Click here to see how you can learn while you earn.

    Khiron Cannabis Co To Debut South Of The Border, Obtains High-THC Extract Export Quotas For Mexico
    Vertically integrated cannabis company Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX: KHRNF) received a quota to export over 700 kg of high-THC extract to Mexico.

    Leveraging the Company's designation in Colombia as a National Strategic Project, Khiron Colombia SAS obtained permission to include Mexico as a destination country within its international export quota.

    "Our goal is to improve the lives of 1 million patients by 2024 and Mexico remains a very important part of that plan," Alvaro Torres, the company's CEO and director said Monday.

    The advances in regulatory and supply chain significantly stepped up the process of Khiron's entry into the Mexican cannabis market.

    New Traders Swear By Benzinga Options

    ★★★★★
    "9 out of 10 trades are winners!" - Cameron W. Houston, TX

    We sift through this volatile market for consistent trades so you don't have to. Get Benzinga Options: Starter Edition to follow Benzinga's high-conviction options trades.

    Click here to get my trades!

    "Thanks to our status as a National Strategic Project, Mexico is now a destination country within our international THC quota, which is expected to accelerate first sales by several months," Torres continued.

    Moreover, Khiron also closed several deals with "a world-class partner" to manufacture finished medical cannabis products in Mexico. Torres said that the partner agreed to assist with the import and export process as well.

    "As we continue to advance our proven Zerenia clinic strategy in Mexico, we look forward to delivering our first products to patients in the coming months," Torres added.

    Earlier this month, Khiron launched in Lima, Peru, its first Zerenia clinic outside of Colombia.

    Zerenia is a fully integrated telehealth portal that successfully rolled out in Colombia. After venturing into Peru's medical cannabis market last year and filling more than 3,000 prescriptions of CBD medical cannabis, Khiron established a strategic partnership with Clinica Montesur, a specialized medical provider in Lima with over 90 physicians and more than 11,000 patient transactions on an annual basis.

    To date, Khiron has sold more than 24,000 prescriptions in Colombia and Peru.
  • E
    Ernest
    Wow! What a surprise…a new stock offering…never saw that coming…
  • P
    Platinum
    I called this dilution perfectly. Called it back in January. So obvious.

    Wonder if this company can ever get around to really starting to grow their revenues